Jim Cramer
Jensen Huang explains why Nvidia’s latest partnership with OpenAI is different
In an interview with CNBC’s Jim Cramer, Nvidia CEO Jensen Huang discussed his company’s new deal with OpenAI, saying it’s the first “direct partnership” with the ChatGPT maker. “This is a partnership that, for the first time, OpenAI is going to buy directly from us,” Huang said. “Usually…a cloud service provider buys from us, and […]
Read More
New signs of a dealmaking comeback: What it means for Goldman Sachs investors
The rebound in Wall Street dealmaking is undeniable. And, for Goldman Sachs , that’s undeniably bullish. Investors got two new reasons to be optimistic about the Club stock this week: Goldman was tapped as a financial advisor in the massive deal to take video game publisher Electronic Arts private, and smaller investment bank Jefferies posted its […]
Read More
Why an analyst downgrade of Wells Fargo does not change our conviction in the stock
Wells Fargo shares have more in the tank despite a downgrade from Wall Street analysts, according to Jim Cramer. The news Morgan Stanley analysts on Monday lowered their Wells Fargo rating to an equal weight hold from an overweight buy. They cited a lack of catalysts for the stock now that Wells Fargo’s $1.95 trillion […]
Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]
Read More
Jim Cramer says Eli Lilly’s obesity pill could be more of a ‘lifetime drug’ than shots
Don’t count out Eli Lilly’s oral GLP-1 drug for obesity and diabetes just yet, according to CNBC’s Jim Cramer . That was his takeaway following the latest study involving Lilly’s orforglipron, the experimental pill that has been the subject of Wall Street debate since weight-loss data released in early August came in below investor expectations. […]
Read More
How BlackRock and Goldman Sachs are bringing Wall Street’s hottest asset class to 401(k)s
Wall Street’s largest firms are championing a new cause. They are bringing alternative assets — once reserved for the ultra-wealthy — to the portfolios of individual investors. Chief among the proponents are BlackRock and Goldman Sachs. But, as is usually the case in investing, the potential of greater returns comes at a risk. “The alternative […]
Read More
Why Fed chief Powell’s rate cut signal lifted our non-tech stocks the most
It was a topsy-turvy week for Wall Street, saved by a big Friday rally. The market was looking at a weekly loss at Thursday’s close. But a day later, Federal Reserve Chairman Jerome Powell came through, hinting at possible interest rate cuts ahead. His speech on Friday at the central bank’s economic symposium in Jackson […]
Read More
How dealmaking king Goldman Sachs aims to dominate another corner of Wall Street
Goldman Sachs has long been considered the king of Wall Street dealmaking. Now, the bank is increasing its focus on another target: managing money for wealthy clients and institutions. Investment banking services, like underwriting initial public offerings (IPO) and advising mergers and acquisitions (M & A), have long been Goldman’s bread and butter. In fact, […]
Read More
We’re upgrading our rating on Disney thanks to a misguided market reaction to earnings
Disney shares are under pressure Wednesday after the entertainment giant reported mixed quarterly results. We think it’s an opportunity. Revenue in the three months ended June 28 increased 2% year over year to $23.65 billion, missing expectations of $23.73 billion, according to LSEG. Adjusted earnings per share (EPS) in the fiscal 2025 third quarter totaled […]
Read More
Honeywell’s post-earnings drop was disrespectful. Here’s where we stand on the stock
An unwarranted post-earnings decline in Honeywell shares on Thursday presented a buying opportunity for new investors ahead of the conglomerate’s breakup into three publicly traded companies. Revenue in the second quarter ended June 30 rose 8.1% year over year to $10.35 billion, topping expectations of $10.07 billion, according to market data service LSEG. Organic sales […]
Read More